Prot #CXA-ICU-14-01: A Phase 1, Prospective, Multi-Center, Open-Label Study to Assess the Plasma Pharmacokinetics and Lung Penetration of Intravenous (IV) Ceftolozane/Tazobactam in Critically Ill Patients

Project: Research project

Project Details

StatusFinished
Effective start/end date4/2/15 → 4/2/18

Funding

  • Quintiles, Inc. (Prot #CXA-ICU-14-01 // Prot #CXA-ICU-14-01)
  • Cubist Pharmaceuticals, Inc. (Prot #CXA-ICU-14-01 // Prot #CXA-ICU-14-01)